{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:06:00Z","timestamp":1770224760728,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM140635"],"award-info":[{"award-number":["R01GM140635"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM106999"],"award-info":[{"award-number":["T32GM106999"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"National Library of Medicine","doi-asserted-by":"publisher","award":["R01LM012222"],"award-info":[{"award-number":["R01LM012222"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"National Library of Medicine","doi-asserted-by":"publisher","award":["R01LM012482"],"award-info":[{"award-number":["R01LM012482"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bcp.2021.114824","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T17:37:29Z","timestamp":1636133849000},"page":"114824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs"],"prefix":"10.1016","volume":"194","author":[{"given":"Mary Alexandra","family":"Schleiff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison","family":"Blue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Mark","family":"Schleiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Boysen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grover Paul","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2021.114824_b0005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/dmd.114.058834","article-title":"Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their intercorrelations: a meta-analysis","volume":"42","author":"Achour","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2021.114824_b0010","first-page":"347","article-title":"Drugs containing halogen atoms: toxicity and lack of toxicity","volume":"61","author":"Adriani","year":"1972","journal-title":"J. Med. Assoc. Ga"},{"issue":"8","key":"10.1016\/j.bcp.2021.114824_b0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-015-0392-z","article-title":"Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology","volume":"75","author":"Altman","year":"2015","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.bcp.2021.114824_b0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","article-title":"Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib","volume":"31","author":"Amaya","year":"2018","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2021.114824_b0025","doi-asserted-by":"crossref","first-page":"113661","DOI":"10.1016\/j.bcp.2019.113661","article-title":"Comprehensive Kinetic and Modeling Analyses Revealed CYP2C9 and 3A4 Determine Terbinafine Metabolic Clearance and Bioactivation","volume":"170","author":"Barnette","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114824_b0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.toxlet.2020.11.015","article-title":"Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam","volume":"338","author":"Barnette","year":"2021","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2021.114824_b0035","doi-asserted-by":"crossref","first-page":"152478","DOI":"10.1016\/j.tox.2020.152478","article-title":"Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam","volume":"440","author":"Barnette","year":"2020","journal-title":"Toxicology"},{"key":"10.1016\/j.bcp.2021.114824_b0040","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/ph14050472","article-title":"Descriptors of cytochrome inhibitors and useful machine learning based methods for the design of safer drugs","volume":"14","author":"Beck","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2021.114824_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00672","article-title":"Novel diphenylamine analogs induce mesenchymal to epithelial transition in triple negative breast cancer","volume":"9","author":"Bhatt","year":"2019","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114824_b0050","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.drudis.2020.07.009","article-title":"Acyl glucuronide reactivity in perspective","volume":"25","author":"Bradshaw","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bcp.2021.114824_b0055","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15284-1","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2021.114824_b0060","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1021\/acs.chemrev.5b00484","article-title":"The halogen bond","volume":"116","author":"Cavallo","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2021.114824_b0065","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2021.114824_b0070","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discovery Today"},{"issue":"9","key":"10.1016\/j.bcp.2021.114824_b0075","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/0006-2952(95)00043-Y","article-title":"The effect of varying halogen substituent patterns on the cytochrome P450 catalysed dehalogenation of 4-halogenated anilines to 4-aminophenol metabolites","volume":"49","author":"Cnubben","year":"1995","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114824_b0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11883-000-0090-4","article-title":"Does differing metabolism by cytochrome P450 have clinical importance?","volume":"2","author":"Davidson","year":"2000","journal-title":"Curr. Atheroscler. Rep."},{"issue":"645","key":"10.1016\/j.bcp.2021.114824_b0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3399\/bjgp16X684433","article-title":"The dangers of NSAIDs: look both ways","volume":"66","author":"Davis","year":"2016","journal-title":"Br. J. Gen. Pract."},{"issue":"6","key":"10.1016\/j.bcp.2021.114824_b0090","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/acs.chemrestox.9b00006","article-title":"CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches","volume":"32","author":"Davis","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"03","key":"10.1016\/j.bcp.2021.114824_b0095","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0444.1000495","article-title":"1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology","volume":"08","author":"Montellano","year":"2018","journal-title":"Med Chem (Los Angeles)"},{"key":"10.1016\/j.bcp.2021.114824_b0100","unstructured":"J. Easterbrook, C. Lu, Y. Sakai, A.P. Li, 000. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metabolism and Disposition 4."},{"issue":"1-2","key":"10.1016\/j.bcp.2021.114824_b0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0009-2797(02)00052-2","article-title":"Idiosyncratic NSAID drug induced oxidative stress","volume":"142","author":"Galati","year":"2002","journal-title":"Chem. Biol. Interact."},{"issue":"4","key":"10.1016\/j.bcp.2021.114824_b0110","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1021\/tx800368n","article-title":"In Vitro Screening of 50 Highly Prescribed Drugs for Thiol Adduct Formation: Comparison of Potential for Drug-Induced Toxicity and Extent of Adduct Formation","volume":"22","author":"Gan","year":"2009","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114824_b0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","article-title":"A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience","volume":"15","author":"Goldkind","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.bcp.2021.114824_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.arabjc.2010.12.006","article-title":"Spectrophotometric and spectrofluorometric methods for the determination of non-steroidal anti-inflammatory drugs: A review","volume":"6","author":"Gouda","year":"2013","journal-title":"Arabian J. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2021.114824_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114824_b0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bcp.2013.12.003","article-title":"CYP2E1 hydroxylation of aniline involves negative cooperativity","volume":"87","author":"Hartman","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114824_b0135","article-title":"Adverse Events Associated with NSAIDs","volume":"33","author":"Hawboldt","year":"2008","journal-title":"US Pharmacist"},{"key":"10.1016\/j.bcp.2021.114824_b0140","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen Atoms in the Modern Medicinal Chemistry: Hints for the Drug Design","volume":"11","author":"Hernandes","year":"2010","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.bcp.2021.114824_b0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/tx8002356","article-title":"Bioactivation of Lumiracoxib by Peroxidases and Human Liver Microsomes: Identification of Multiple Quinone Imine Intermediates and GSH Adducts","volume":"22","author":"Kang","year":"2009","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114824_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-011-0024-2","article-title":"Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity","volume":"36","author":"Khojasteh","year":"2011","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.bcp.2021.114824_b0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bcp.2021.114824_b0160","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1124\/dmd.110.033894","article-title":"Effect of Regular Organic Solvents on Cytochrome P450-Mediated Metabolic Activities in Rat Liver Microsomes","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2021.114824_b0165","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/acs.chemrestox.0c00374","article-title":"DeepDILI: Deep Learning-Powered Drug-Induced Liver Injury Prediction Using Model-Level Representation","volume":"34","author":"Li","year":"2021","journal-title":"Chem. Res. Toxicol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114824_b0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.toxlet.2009.01.005","article-title":"The relationship between diphenylamine structure and NSAIDs-induced hepatocytes injury","volume":"186","author":"Li","year":"2009","journal-title":"Toxicol. Lett."},{"issue":"2","key":"10.1016\/j.bcp.2021.114824_b0175","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/dmd.107.019018","article-title":"In vitro metabolic activation of lumiracoxib in rat and human liver preparations","volume":"36","author":"Li","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"33","key":"10.1016\/j.bcp.2021.114824_b0180","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1021\/bi00033a007","article-title":"The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling","volume":"34","author":"Mancy","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2021.114824_b0185","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0006-2952(99)00163-X","article-title":"Diphenylamine as an important structure of nonsteroidal anti-inflammatory drugs to uncouple mitochondrial oxidative phosphorylation","volume":"58","author":"Masubuchi","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114824_b0190","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/molecules22091397","article-title":"Looking back, looking forward at halogen bonding in drug discovery","volume":"22","author":"Mendez","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2021.114824_b0195","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2174\/138920009790820129","article-title":"New insights into the structural features and functional relevance of human cytochrome P450 2C9","volume":"10","author":"Mo","year":"2009","journal-title":"Part I. Curr Drug Metab"},{"issue":"2","key":"10.1016\/j.bcp.2021.114824_b0200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00498254.2014.945196","article-title":"Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays","volume":"45","author":"Nirogi","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcp.2021.114824_b0205","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1440-1746.2011.07036.x","article-title":"Severe acute liver injury associated with lumiracoxib","volume":"27","author":"Pillans","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114824_b0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/bdd.720","article-title":"Acyl glucuronides: the good, the bad and the ugly","volume":"31","author":"Regan","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"issue":"53","key":"10.1016\/j.bcp.2021.114824_b0215","doi-asserted-by":"crossref","first-page":"44581","DOI":"10.1074\/jbc.M112.424895","article-title":"Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19","volume":"287","author":"Reynald","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114824_b0220","first-page":"3","article-title":"Solubility of Buffers in Aqueous-Organic Eluents for Reversed-Phase Liquid Chromatography","volume":"22","author":"Schellinger","year":"2004","journal-title":"LCGC North Am."},{"issue":"2","key":"10.1016\/j.bcp.2021.114824_b0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/dmd.120.000254","article-title":"Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics","volume":"49","author":"Schleiff","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2021.114824_b0230","doi-asserted-by":"crossref","first-page":"152832","DOI":"10.1016\/j.tox.2021.152832","article-title":"Impacts of diphenylamine NSAID halogenation on bioactivation risks","volume":"458","author":"Schleiff","year":"2021","journal-title":"Toxicology"},{"issue":"25","key":"10.1016\/j.bcp.2021.114824_b0235","doi-asserted-by":"crossref","first-page":"17227","DOI":"10.1074\/jbc.M802180200","article-title":"Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid","volume":"283","author":"Schoch","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114824_b0240","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1021\/tx9802365","article-title":"Metabolic Activation of Diclofenac by Human Cytochrome P450 3A4: Role of 5-Hydroxydiclofenac","volume":"12","author":"Shen","year":"1999","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2021.114824_b0245","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2021.114824_b0250","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.taap.2016.04.013","article-title":"An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure","volume":"302","author":"Spaggiari","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"20","key":"10.1016\/j.bcp.2021.114824_b0255","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1007\/s00216-014-7915-4","article-title":"Phenotyping of CYP450 in human liver microsomes using the cocktail approach","volume":"406","author":"Spaggiari","year":"2014","journal-title":"Analytical and Bioanalytical Chemistry; Heidelberg"},{"issue":"101","key":"10.1016\/j.bcp.2021.114824_b0260","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jpba.2014.03.018","article-title":"A cocktail approach for assessing the in vitro activity of human cytochrome P450s: An overview of current methodologies","volume":"2014","author":"Spaggiari","year":"2014","journal-title":"Journal of Pharmaceutical and Biomedical Analysis, JPBA Reviews"},{"key":"10.1016\/j.bcp.2021.114824_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5253623","article-title":"Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials [WWW Document]","volume":"2018","author":"Sriuttha","year":"2018","journal-title":"International Journal of Hepatology"},{"key":"10.1016\/j.bcp.2021.114824_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5253623","article-title":"Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials","volume":"2018","author":"Sriuttha","year":"2018","journal-title":"Int. J. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114824_b0275","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/tx9802217","article-title":"Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac \u2020","volume":"12","author":"Tang","year":"1999","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114824_b0280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17474124.2018.1383154","article-title":"The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury","volume":"12","author":"Thakkar","year":"2018","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"8","key":"10.1016\/j.bcp.2021.114824_b0285","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-006-0155-6","article-title":"The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone","volume":"62","author":"Tornio","year":"2006","journal-title":"European Journal of Clinical Pharmacology; Heidelberg"},{"key":"10.1016\/j.bcp.2021.114824_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2017.03.003","article-title":"Acyl glucuronide metabolites: Implications for drug safety assessment","volume":"272","author":"Van Vleet","year":"2017","journal-title":"Toxicol. Lett."},{"issue":"12","key":"10.1016\/j.bcp.2021.114824_b0295","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1021\/tx500288b","article-title":"Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases","volume":"27","author":"Venkataraman","year":"2014","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114824_b0300","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/jm3012068","article-title":"Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology","volume":"56","author":"Wilcken","year":"2013","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2021.114824_b0305","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/dmd.104.003095","article-title":"Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides","volume":"33","author":"Yan","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2021.114824_b0310","doi-asserted-by":"crossref","first-page":"113946","DOI":"10.1016\/j.bcp.2020.113946","article-title":"Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer","volume":"177","author":"Yu","year":"2020","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:10:54Z","timestamp":1762096254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221004408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":62,"alternative-id":["S0006295221004408"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114824","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114824"}}